Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX; -0ABW), a Stockholm-headquartered rare disease pharmaceutical company, announced on 4 November 2026 that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 190 million (approximately SEK 1,900 million). The PRV was granted by the U.S. Food and Drug Administration on 28 September 2026 in connection with the FDA approval of EMCITATE® (tiratricol), the company's lead product for MCT8 deficiency. The transaction remains subject to customary closing conditions, including expiry of the applicable Hart-Scott-Rodino antitrust waiting period, making the timing of final completion a key variable for investors to monitor.

Key Points

  • Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX; -0ABW)
  • The company has signed a definitive agreement to sell its FDA Rare Pediatric Disease Priority Review Voucher for USD 190 million (approximately SEK 1,900 million) in gross proceeds
  • Former owners of subsidiary RTTI are entitled to approximately 50 per cent of net proceeds as an earnout, stemming from Egetis' 2020 acquisition of EMCITATE®
  • Investors should watch for confirmation that Hart-Scott-Rodino antitrust conditions have been satisfied and the transaction has formally closed

EMCITATE® FDA Approval Triggers USD 190 Million PRV Sale for Egetis Therapeutics

The PRV being sold was awarded to Egetis following FDA approval of EMCITATE® (tiratricol) on 28 September 2026 for the treatment of peripheral thyrotoxicosis in adults and paediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, a rare and life-shortening genetic disorder. EMCITATE® holds marketing authorisations in both the European Union and the United States, making it the first and only approved treatment for this condition. The agreement to monetise the PRV at USD 190 million represents a significant non-dilutive capital event for the company, which operates across Stockholm, the U.S., and Europe.

Earnout Obligation to Former RTTI Owners Reduces Net Proceeds from Voucher Sale

Egetis acquired EMCITATE® through its purchase of Rare Thyroid Therapeutics International AB (RTTI) in 2020. Under the terms of that original acquisition, the former owners of RTTI retain an earnout entitlement of approximately 50 per cent of the net proceeds generated from any PRV sale. The announcement confirms that RTTI, now a wholly-owned subsidiary, is a co-party to the definitive asset purchase agreement. Investors should therefore note that Egetis' share of the USD 190 million gross proceeds will be materially reduced once this earnout and associated transaction costs are accounted for, though the exact net figure was not disclosed in the announcement.

Hart-Scott-Rodino Antitrust Clearance Required Before Closing Can Complete

The transaction is subject to customary closing conditions, most notably the expiry of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Until this regulatory clearance is obtained, the sale cannot formally complete. Egetis Therapeutics is a commercial-stage pharmaceutical company focused exclusively on rare diseases with significant unmet medical need, combining late-stage development, regulatory expertise, and commercial infrastructure. The outcome of the antitrust review process represents the primary near-term risk to completion of this transaction as disclosed in the announcement.